{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:59:03Z","timestamp":1784228343089,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Multi\/extensively drug-resistant bacterial infections have recently increased and new antimicrobial options are needed for difficult-to-treat infections. Ceftazidime\/avibactam (CZA) has been approved for patients 3 months to 18 years of age, but real-life data on its off-label use in neonates and young infants are still scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials:\u2002<\/jats:title>\n            <jats:p>We report demographic, clinical and microbiologic data as well as outcome and safety of all cases of infants treated with CZA between January 1, 2021 and September 30, 2022 in a tertiary neonatal intensive care unit. We also review all neonatal cases previously reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-one patients [17 males, with median gestational age 29<jats:sup>+2<\/jats:sup> (IQR 6<jats:sup>+6<\/jats:sup>) weeks] received 31 CZA courses at a dose of 20\u201350\u2009mg\/kg\/dose of ceftazidime q8h for suspected or proved multi\/extensively drug-resistant infections. Median postnatal age at the onset of treatment was 44 days (IQR: 94 days). Twelve bacteremias, 2 urinary tract infections and 1 ventilator-acquired pneumonia were recorded. Twelve (39%) treatments were targeted, while 19 (61%) were empirically started due to known colonization with <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic> carbapenemase-producing Gram-negative bacteria. All patients had received multiple antibiotics prior and concomitantly with CZA. The most common pathogen identified at targeted administrations was carbapenem-resistant <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic> (83%). No serious adverse events attributed to the drug were detected. Twenty-one courses of CZA administration to 20 neonates with a median gestational age of 28.5 (IQR 3.5) weeks were previously reported without significant related adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Favorable clinical and microbiologic responses in neonatal intensive care unit patients treated with CZA off-label were observed without significant and unexpected adverse events in critically ill neonates.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004247","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:00:33Z","timestamp":1705701633000},"page":"e149-e154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Off-label Use of Ceftazidime\/Avibactam in Neonatal Intensive Care Unit: A Real-life Experience and Literature Review"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8333-3318","authenticated-orcid":false,"given":"Argyro","family":"Ftergioti","sequence":"first","affiliation":[{"name":"From the Infectious Diseases Unit, 3rd Department Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2064-771X","authenticated-orcid":false,"given":"Melania","family":"Degli Antoni","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-9537","authenticated-orcid":false,"given":"Angeliki","family":"Kontou","sequence":"additional","affiliation":[{"name":"1st Department of Neonatology and Intensive Care Unit, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-9295","authenticated-orcid":false,"given":"Maria","family":"Kourti","sequence":"additional","affiliation":[{"name":"From the Infectious Diseases Unit, 3rd Department Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Pantzartzi","sequence":"additional","affiliation":[{"name":"From the Infectious Diseases Unit, 3rd Department Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-2495","authenticated-orcid":false,"given":"Charalampos","family":"Zarras","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hippokration General Hospital, Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-0510","authenticated-orcid":false,"given":"Eleni","family":"Agakidou","sequence":"additional","affiliation":[{"name":"1st Department of Neonatology and Intensive Care Unit, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-6343","authenticated-orcid":false,"given":"Kosmas","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"1st Department of Neonatology and Intensive Care Unit, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-364X","authenticated-orcid":false,"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"From the Infectious Diseases Unit, 3rd Department Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-451X","authenticated-orcid":false,"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"From the Infectious Diseases Unit, 3rd Department Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41390-021-01745-7","article-title":"Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management.","volume":"91","author":"Flannery","year":"2022","journal-title":"Pediatr Res"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jpids\/piz085","article-title":"Treatment of carbapenem-resistant enterobacteriaceae infections in children.","volume":"9","author":"Chiotos","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1469-0691.2009.03115.x","article-title":"Controlling the spread of carbapenemase-producing gram-negatives: therapeutic approach and infection control.","volume":"16","author":"Carmeli","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/INF.0000000000002807","article-title":"Successful treatment of pandrug-resistant Klebsiella pneumoniae infection with ceftazidime-avibactam in a preterm infant: a case report.","volume":"39","author":"Coskun","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/08971900221087131","article-title":"Off-label use of ceftazidime-avibactam in a premature infant with multidrug-resistant Klebsiella pneumoniae infection: a case report.","volume":"36","author":"Nascimento","year":"2022","journal-title":"J Pharm Pract"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"804","DOI":"10.23736\/S0375-9393.19.13521-3","article-title":"Ceftazidine-avibactam salvage therapy in newborn with KPC-producing Klebsiella pneumoniae invasive infections.","volume":"85","author":"Esposito","year":"2019","journal-title":"Minerva Anestesiol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/IDR.S320056","article-title":"Carbapenem-resistant Klebsiella pneumoniae osteomyelitis treated with ceftazidime-avibactam in an infant: a case report.","volume":"14","author":"Ji","year":"2021","journal-title":"Infect Drug Resist"},{"key":"R16-20250614","first-page":"192","article-title":"Intravenous ceftazidime-avibactam in extremely premature neonates with carbapenem-resistant enterobacteriaceae: two case reports.","volume":"27","author":"Asfour","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/antibiotics12071169","article-title":"Ceftazidime-avibactam treatment for Klebsiella pneumoniae bacteremia in preterm infants in NICU: a clinical experience.","volume":"12","author":"Marino","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0000000000002344","article-title":"Use of Ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children.","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1097\/INF.0000000000004124","article-title":"The challenge of extensively drug-resistant (XDR) gram-negative pathogens in children: newer antibiotics and when to use them for empiric and definitive therapy.","volume":"42","author":"Iosifidis","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"e02183","DOI":"10.1128\/AAC.02183-19","article-title":"Carbapenem-resistant gram-negative bacterial infections in children.","volume":"64","author":"Aguilera-Alonso","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program.","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program.","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","article-title":"Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms.","volume":"55","author":"Sy","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/antibiotics12061072","article-title":"Use of newer and repurposed antibiotics against gram-negative bacteria in neonates.","volume":"12","author":"Kontou","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653 months to.","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to.","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/antibiotics12081302","article-title":"Off-Label use of Ceftazidime\/Avibactam for the treatment of pan-drug-resistant Klebsiella pneumoniae in a neonate: case report and literature review. Antibiotics 2023, Vol 12, Page 1302.","volume":"12","author":"Mangarov","year":"2023","journal-title":"Antibiotics (Basel)"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:15Z","timestamp":1749945615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004247","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}